A novel compound VSC2 has anti-inflammatory and antioxidant properties in microglia and in Parkinson's disease animal model

British Journal of Pharmacology

Volumn 172, Issue 4, 2015, Pages 1087-1100

  Lee, Ji Ae ^a   Kim, Ji Hyun ^a   Woo, Seo Yeon ^b   Son, Hyo Jin ^a   Han, Se Hee ^a   Jang, Bo Ko ^b   Choi, Ji Won ^b   Kim, Dong Jin ^b   Park, Ki Duk ^b   Hwang, Onyou ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 [(2 METHOXYPHENYL)SULFONYL]VINYL] 2 CHLOROBENZENE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CYCLOOXYGENASE 2; GLUTAMATE CYSTEINE LIGASE; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LIPOPOLYSACCHARIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SULFONE DERIVATIVE; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 1-(2-((2-METHOXYPHENYL)SULFONYL)VINYL)-2-CHLOROBENZENE; CYTOSKELETON PROTEIN; KEAP1 PROTEIN, MOUSE; NFE2L2 PROTEIN, MOUSE; NITRIC OXIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SULFONE; TUMOR NECROSIS FACTOR; VINYL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOWN REGULATION; ENZYME ACTIVITY; ENZYME SYNTHESIS; IN VIVO STUDY; MALE; MICROGLIA; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; UPREGULATION; ANIMAL; C57BL MOUSE; CELL LINE; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CELL LINE; CYTOSKELETAL PROTEINS; DISEASE MODELS, ANIMAL; INTERLEUKIN-1BETA; MALE; MICE, INBRED C57BL; MICROGLIA; NF-E2-RELATED FACTOR 2; NF-KAPPA B; NITRIC OXIDE; PARKINSON DISEASE; SULFONES; TUMOR NECROSIS FACTOR-ALPHA; VINYL COMPOUNDS;

EID: 84921717510     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12973     Document Type: Article

References (41)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al (2013). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
2. Blandini F (2013). Neural and immune mechanisms in the pathogenesis of Parkinson's disease. J Neuroimmune Pharmacol 8: 189-201.
3. Botta D, White CC, Vliet-Gregg P, Mohar I, Shi S, McGrath MB et al. (2008). Modulating GSH synthesis using glutamate cysteine ligase transgenic and gene-targeted mice. Drug Metab Rev 40: 465-477.
4. Bukhari SN, Jantan I, Jasamai M (2013). Anti-inflammatory trends of 1, 3-diphenyl-2-propen-1-one derivatives. Mini Rev Med Chem 13: 87-94.
5. Cho Y, Son HJ, Kim EM, Choi JH, Kim ST, Ji IJ et al. (2009). Doxycycline is neuroprotective against nigral dopaminergic degeneration by a dual mechanism involving MMP-3. Neurotox Res 16: 361-371.
6. Clarke JD, Hsu A, Williams DE, Dashwood RH, Stevens JF, Yamamoto M et al. (2011). Metabolism and tissue distribution of sulforaphane in Nrf2 knockout and wild-type mice. Pharm Res 28: 3171-3179.
7. Dinkova-Kostova AT, Massiah MA, Bozak RE, Hicks RJ, Talalay P (2001). Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc Natl Acad Sci U S A 98: 3404-3409.
8. Fourquet S, Guerois R, Biard D, Toledano MB (2010). Activation of NRF2 by nitrosative agents and H2O2 involves KEAP1 disulfide formation. J Biol Chem 285: 8463-8471.
9. Franklin KBJ, Paxinos G (1997). The Mouse Brain in Stereotaxic Coordinates. Academic Press: San Diego, pp. 59-67.
10. Gloire G, Legrand-Poels S, Piette J (2006). NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 72: 1493-1505.
11. Hara H, Ohta M, Adachi T (2006). Apomorphine protects against 6-hydroxydopamine-induced neuronal cell death through activation of the Nrf2-ARE pathway. J Neurosci Res 84: 860-866.
12. Hwang O (2013). Role of oxidative stress in Parkinson's disease. Exp Neurobiol 22: 11-17.
13. Innamorato NG, Rojo AI, García-Yagüe AJ, Yamamoto M, de Ceballos ML, Cuadrado A (2008). The transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol 181: 680-689.
14. Innamorato NG, Jazwa A, Rojo AI, García C, Fernández-Ruiz J, Grochot-Przeczek A et al. (2010). Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. PLoS ONE 5: e11838.
15. Jazwa A, Rojo AI, Innamorato NG, Hesse M, Fernández-Ruiz J, Cuadrado A (2011). Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antioxid Redox Signal 14: 2347-2360.
16. Jeong WS, Kim IW, Hu R, Kong AN (2004). Modulatory properties of various natural chemopreventive agents on the activation of NF-kappaB signaling pathway. Pharm Res 21: 661-670.
17. Kaidery NA, Banerjee R, Yang L, Smirnova NA, Hushpulian DM, Liby KT et al. (2013). Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease. Antioxid Redox Signal 18: 139-157.
18. Kang CH, Kim MJ, Seo MJ, Choi YH, Jo WS, Lee KT et al. (2013). 5-Hydroxy-3,6,7,8,3′4′-hexamethoxyflavone inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-κB suppression and Nrf-2-dependent heme oxygenase-1 induction. Food Chem Toxicol 57: 119-125.
19. Kaspar JW, Niture SK, Jaiswal AK (2009). Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med 47: 1304-1309.
20. Kim SS, Lim J, Bang Y, Gal J, Lee SU, Cho YC et al. (2012). Licochalcone E activates Nrf2/antioxidant response element signaling pathway in both neuronal and microglial cells: therapeutic relevance to neurodegenerative disease. J Nutr Biochem 23: 1314-1323.
21. Koh K, Kim J, Jang YJ, Yoon K, Cha Y, Lee HJ et al. (2011). Transcription factor Nrf2 suppresses LPS-induced hyperactivation of BV-2 microglial cells. J Neuroimmunol 233: 160-167.
22. Lee IS, Lim J, Gal J, Kang JC, Kim HJ, Kang BY et al. (2011). Anti-inflammatory activity of xanthohumol involves heme oxygenase-1 induction via NRF2-ARE signaling in microglial BV2 cells. Neurochem Int 58: 153-160.
23. Lin W, Wu RT, Wu T, Khor TO, Wang H, Kong AN (2008). Sulforaphane suppressed LPS-induced inflammation in mouse peritoneal macrophages through Nrf2 dependent pathway. Biochem Pharmacol 76: 967-973.
24. Loane DJ, Byrnes KR (2010). Role of microglia in neurotrauma. Neurother 7: 366-377.
25. Lu SC (2009). Regulation of glutathione synthesis. Mol Aspects Med 30: 42-59.
26. Morroni F, Tarozzi A, Sita G, Bolondi C, Zolezzi Moraga JM, Cantelli-Forti G et al. (2013). Neuroprotective effect of sulforaphane in 6-hydroxydopamine-lesioned mouse model of Parkinson's disease. Neurotoxicology 36: 63-71.
27. Paine A, Eiz-Vesper B, Blasczyk R, Immenschuh S (2010). Signaling to heme oxygenase-1 and its anti-inflammatory therapeutic potential. Biochem Pharmacol 80: 1895-1903.
28. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
29. Rojo AI, Innamorato NG, Martín-Moreno AM, De Ceballos ML, Yamamoto M, Cuadrado A (2010). Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 58: 88-98.
30. Rushworth SA, MacEwan DJ, O'Connell MA (2008). Lipopolysaccharide-induced expression of NAD(P)H: quinone oxidoreductase 1 and heme oxygenase-1 protects against excessive inflammatory responses in human monocytes. J Immunol 181: 6730-6737.
31. Sierra A, Gottfried-Blackmore AC, McEwen BS, Bulloch K (2007). Microglia derived from aging mice exhibit an altered inflammatory profile. Glia 55: 412-424.
32. Son HJ, Lee JA, Shin N, Choi JH, Seo JW, Chi DY et al. (2012). A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP. Br J Pharmacol 165: 2213-2227.
33. Stuckenholz V, Bacher M, Balzer-Geldsetzer M, Alvarez-Fischer D, Oertel WH, Dodel RC et al. (2013). The α7 nAChR agonist PNU-282987 reduces inflammation and MPTP-induced nigral dopaminergic cell loss in mice. J Parkinsons Dis 3: 161-172.
34. Tansey MG, Goldberg MS (2010). Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37: 510-518.
35. Teismann P, Ferger B (2001). Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39: 167-174.
36. Thimmulappa RK, Lee H, Rangasamy T, Reddy SP, Yamamoto M, Kensler TW et al. (2006). Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest 116: 984-995.
37. Villeneuve NF, Lau A, Zhang DD (2010). Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases. Antioxid Redox Signal 13: 1699-1712.
38. Wakabayashi N, Slocum SL, Skoko JJ, Shin S, Kensler TW (2010). When NRF2 talks, who's listening? Antioxid Redox Signal 13: 1649-1663.
39. Woo SY, Kim JH, Moon MK, Han SH, Yeon SK, Choi JW et al. (2014). Discovery of vinyl sulfones as a novel class of neuroprotective agents toward Parkinson's disease therapy. J Med Chem 57: 1473-1487.
40. Wu RP, Hayashi T, Cottam HB, Jin G, Yao S, Wu CC et al. (2010). Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 107: 7479-7484.
41. Zhou HF, Liu XY, Niu DB, Li FQ, He QH, Wang XM (2005). Triptolide protects dopaminergic neurons from inflammation-mediated damage induced by lipopolysaccharide intranigral injection. Neurobiol Dis 18: 441-449.